Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells

Archives of Pharmacal Research

Volumn 31, Issue 3, 2008, Pages 370-376

  Han, Shinha ^a   Kim, Kwanghee ^a   Song, Youngcheon ^a   Kim, Hyunyul ^a   Kwon, Jeunghak ^a   Lee, Young Hee ^b   Lee, Chong Kil ^b   Lee, Sang Jin ^a   Ha, Namjoo ^a   Kim, Kyungjae ^a  

^a Sahmyook University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

Auranofin; Cross presentation; Dendritic cells; Immunosuppression; MHC

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; H 2KB PROTEIN, MOUSE; H-2KB PROTEIN, MOUSE; H2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; I A(B) ANTIGEN, MOUSE; I-A(B) ANTIGEN, MOUSE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; OVA 8; OVA-8; OVALBUMIN; PEPTIDE FRAGMENT;

ANIMAL; ANTIGEN PRESENTATION; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL LINE; DENDRITIC CELL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MOUSE; PHAGOCYTOSIS;

ANIMALS; ANTIGEN PRESENTATION; ANTIRHEUMATIC AGENTS; AURANOFIN; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; PEPTIDE FRAGMENTS; PHAGOCYTOSIS;

EID: 46249100419     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1166-9     Document Type: Article

References (26)

1. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., and Palucka, K., Immunobiology of dendritic cells. Annu. Rev. Immunol., 18, 767-811 (2000).
2. Berglof, F. E., Berglof, K., and Walz, D. T., Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J. Rheumatol., 5, 68-74 (1978).
3. Bernhard, G. C., Auranofin therapy in rheumatoid arthritis. J. Lab. Clin. Med., 100, 167-177 (1982).
4. Bevan. M. J., Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med., 143, 1283-1288 (1976).
5. Blodgett, R. C., Heuer, M. A., and Pietrusko, R. G., Auranofin: a unique oral chrysotherapeutic agent. Semin. Arthritis Rheum., 13, 255-273 (1984).
6. Blondeson. J., The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen. Pharmacol., 29, 127-150 (1997).
7. Chefalo, P. J., Grandea, A. G., Kaer, L. V., and Harding, C. V., Tapasin-/-and TAP1-/-macrophages are deficient in vacuolar alternate class I MHC (MHC-I) processing due to decreased MHC-I stability at phagolysosomal pH. J. Immunol., 170, 5825-5833 (2003).
8. Cyong, J. and Otsuka, Y. A., A pharmacological study of the anti-inflammatory activity of Chinese herbs. A review. Acupunct. Electrother. Res., 7, 173-202 (1982).
9. Day, P. M., Esquivel, F., Lukszo, J., Bennink, R., and Yewdell, J. W., Effect of TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules. Immunity., 2, 137-147 (1995).
10. Forestier, J., L'aurotherapie dans les rhumatismes chro-niques. Bull. Mem. Soc. Med. Hop. Paris., 53, 323-328 (1929).
11. Graninger, W., Seidl, G., Kovarik, J., Pinggera, W., and Smolen, J. S., Oral gold therapy in a patient with rheumatoid arthritis and preexisting uremia. Arthritis Rheum., 28, 710-712 (1985).
12. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S., Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol., 20, 621-667 (2002).
13. Harding, C. V., Phagocytic processing of antigens for presentation by MHC molecules. Trend. Cell. Biol., 5, 105-109 (1995).
14. Harding, C. V., Collins, D. S., Kanagawa, O., and Unanue, E. R., Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol., 147, 2860-2863 (1991).
15. Haringman, J. J. and Tak, P. P., Chemokine blockade: a new era in the treatment of rheumatoid arthritis? Arthritis Res. Ther., 6, 93-97 (2004).
16. Ho, L. J. and Lai, J. H., Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Curr. Drug Metab., 5, 181-192 (2004).
17. Hunt, L. B., The Figuiers of Montpellier. J. Soc. Study Alch. & Early Chem., 26, 221-223 (1979).
18. Karttunen, J., Sanderson, S., and Shastri, N., Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci., 89, 6020-6024 (1992).
19. Kean, W. F., Hart, L., and Buchanan, W. W., Auranofin. Br. J. Rheumatol., 36, 560-572 (1997).
20. Kean, W. F., Kassam, Y. B., and Lock, C. J. L. et al., Antithrombin activity of gold sodium thiomalate. Clin. Pharmacol. Ther., 35, 627-632 (1984).
21. Lee, Y. R., Yang, I. H., Lee, Y. H., Im, S. A., Song, S., Li, H., Han, K., Kim, K., Eo, S. K., and Lee, C. K., Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood., 105, 3951-3955 (2005).
22. Liu, J., Akahoshi, T., Matsui, T., and Kondo, H., Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis. Inflamm. Res., 49, 445-451 (2000).
23. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R., and Germain, R. N., Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity, 6, 715-726. (1997).
24. Shen, Z., Reznikoff, G., Dranoff, G., and Rock K. L., Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol., 158, 2723-2730 (1997).
25. Simon, L. S., DMARDs in the treatment of rheumatoid arthritis: current agents and future developments. Int. J. Clin. Pract., 54, 243-249 (2000).
26. Walz, E.T., Dimartino, M. J., Griswold, D. E., Intoccia, A. P., and Flanagan, T. L., Biologic actions and pharmacokinetic studies of anofin. Am. J. Med., 75, 90-108 (1983).